跳至主要内容
临床试验/NCT00928395
NCT00928395已完成4 期

Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation

Uroplasty, Inc12 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2009年1月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
50
试验地点
12
主要终点
Proportion of Patients Reporting "Moderately" or "Markedly" Improved on the Global Response Assessment (GRA) at 36 Months as Compared to Baseline

研究概览

简要总结

This is a modified extension study to the SUmiT protocol UPC082008 (NCT00534521) to observe and evaluate long term therapy with PTNS on overactive bladder symptoms. Subjects must have completed the 12 weekly treatments of the original protocol, the 13 week follow up assessment, be randomized to the PTNS arm, and be considered a positive responder with moderate or marked improvement in the SUmiT Trial to be enrolled in this study. All consenting responders will continue with active PTNS therapy at an initially prescribed protocol for approximately 3 months followed by individualized symptom-based frequency of visits as determined by the subject along with their treating clinician, for up to a total of 33 months post initial 12-week therapy for a total of 3 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Subjects who signed the informed consent and were eligible to participate in the original SUmiT Trial
  • •Subjects who were randomized and treated with the active PTNS therapy during their participation in the original SUmiT Trial
  • •Subject must be a positive responder from initial 12 weekly treatments as prescribed in original SUmiT Trial - 13 week GRA questionnaire must indicate "moderately" or "markedly improved" on question #1 of GRA
  • •Subjects must not have started any antimuscarinics treatment since completion of original SUmiT Trial
  • •Subjects must not have started any urologic Botox treatment since completion of original SUmiT Trial
  • •Subjects must remain off all antimuscarinics throughout participation in trial
  • •Subjects must initiate PTNS maintenance therapy within 2 weeks of their last PTNS treatment as part of SUmiT protocol UPC082008
  • •Capable of giving informed consent
  • •Capable and willing to follow all study-related procedures for up to 33 months for a total participation of 3 years

排除标准

  • •Pregnant as confirmed by urine pregnancy test, or plans to become pregnant during the study period
  • •Subjects who were not able or willing to follow original SUmiT Trial study schedule

研究组 & 干预措施

Urgent PC

Active Comparator

The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).

干预措施: Urgent PC (Device)

结局指标

主要结局

Proportion of Patients Reporting "Moderately" or "Markedly" Improved on the Global Response Assessment (GRA) at 36 Months as Compared to Baseline

时间窗: 36 months total

The GRA asked patients, "Compared to the last time you completed this questionnaire, how would you rate your bladder symptoms now?" and was a 7-level Assessment (markedly improved, moderately improved, slightly improved, no change, slightly worse, moderately worse, markedly worse).

次要结局

  • GRA Subset of Individual Bladder Symptom Components to Include Urgency, Frequency and Urge Incontinence.(every three months for 36 months)
  • Change in Voiding Diary Parameters.(every three months for 36 months)
  • Change in OAB-q and SF-36 Questionnaires.(every three months for 36 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验